Uterine Cancer Study Act of 2025
The Uterine Cancer Study Act of 2025 requires the Secretary of Health and Human Services, in coordination with the Commissioner of Food and Drugs (FDA) and the Director of the National Institutes of Health (NIH), to conduct a study on whether chemical hair straighteners are related to uterine cancer, with a focus on the potentially higher incidence among women of color. The bill directs the study to review existing findings, consider impacts across all racial and ethnic backgrounds, disaggregate results by product components (such as dyes/coloring, bleach, highlights, or perms), and evaluate whether FDA should impose additional testing requirements on manufacturers. It establishes timelines: a description of methodology within 45 days of enactment, commencement within 180 days, and a final report within 2 years.
Key Points
- 1Establishes a government-commissioned study led by HHS, with involvement from FDA and NIH.
- 2Focuses on the relationship between chemical hair straighteners and uterine cancer, prioritizing potential disparities affecting women of color.
- 3Requires disaggregation of study results based on specific product components (dyes/coloring, bleach, highlights, perms).
- 4Assesses whether FDA should impose additional testing requirements on manufacturers to improve product safety.
- 5Specifies timelines: methodology description within 45 days, study commencement within 180 days, and a final report within 2 years.